report revenu y/i vs consensu non-gaap
ep y/i vs consensu tweak upward lower end
revenu guidanc non-gaap ep guidanc level still appear
conserv light sale trend share buyback trade new ep
estim view share under-valued
strong led growth newer franchis
product sale y/i consensu xgeva vs
repatha vs sensipar vs drove
much upsid consensu repatha best quarter q/q y/
sinc launch manag reiter optim bright futur driven
expand label updat treatment guidelin improv reimburs
observ chang market share price dynam wake praluent
odyssey outcom trial present march sale sensipar beat consensu
part base upon suppli chain buy in associ recent switch part
part reimburs nonetheless product outlook appear greatli improv
wake settlement gener compani greatli aid follow-on product
parsabiv first quarter sale get run start prolia continu
strong trajectori y/i vs consensu driven volum
gain intend increas market invest maintain strong trajectori
sale neulasta/neupogen vs epogen vs
enbrel vs gener in-lin enbrel sale declin y/i
expect continu trajectori base upon modest decreas volum price
upsid non-gaap ep vs reflect higher product sale lower tax
rate vs reduc share count follow buyback
tweak upward bottom end revenu guidanc
base upon potenti sensipar retain exclus
improv outlook repatha high end guidanc appear achiev
lower end non-gaap ep guidanc also increas
look conserv us light improv revenu
outlook greatli reduc share count confirm addit share
repurchas reduc tax rate outlook
increas revenu non-gaap ep estim slightli top
end guidanc
pleas see page report import disclosur
view better-than-averag pharmaceut compani back biolog
franchis good longev superior geograph mix centric least averag
reason pipelin despit attribut trade discount
averag pharma price-to-earnings multipl believ discount best explain fear
biosimilar competit lack clariti key pipelin asset expect amgen
share outperform competit threat wane relat prospect newer
fda approv decis aimovig may
fda approv decis trastuzumab
phase data infliximab biosimilar
ep growth
price-to-earnings ratio expand toward
revenu growth greater
revenu growth lower project
price-to-earnings ratio pharma group undergo
pipelin contribut substanti
valu model
fail rais dividend pursu
biosimilar launch exceed
among world largest biotechnolog compani product sale
approxim revenu deriv biolog
unlik experi gener competit forese futur major brand includ
enbrel sale neupogen/neulasta denosumab franchis brand
xgeva cancer prolia osteoporosi sale aranesp/epogen
amgen continu invest six therapeut area focu leverag
genet capabl decod databas within pipelin favor repatha
antibodi signific potenti treat sever hypercholesterolemia
repatha fourier outcom data expect drive growth prescrib
patent may keep compet product bay
view one better financi report time believ continu
financi engin share buyback cost control tax save coupl effort
extend compani matur franchis sensipar settlement neulasta
onpro switch posit beat nearer-term financi
expect moder stock perform may possibl base upon alon
substanti out-performance depend upon abil repatha
newer product aimovig gain greater traction one quarter make
trend encourag repatha earli trajectori wake broader outcom
orient label repatha build success perhap aid new treatment
guidelin possibl aha novemb share could benefit substanti
among world largest biotechnolog compani product sale
flat y/i deriv revenu superior
market drug price moreov approxim revenu deriv
biolog unlik experi substitut competit
forese futur major brand includ enbrel sale
neupogen/neulasta xgeva/prolia denosumab aranesp/epogen
near complet seri restructur design expand
oper margin appear track least
meet financi target includ commit return cash
sharehold form dividend stock buyback expect share
outperform compani increas dividend post upsid consensu revenu
ep expect receiv credit newer product repatha
antibodi sever hypercholesterolemia model non-gaap ep
growth commit aggress share repurchas plan
share outstand boost ep growth near term
cog percent sale
 percent sale
sg percent sale
compani report cowen compani estim
fda approv decis aimovig erenumab episod chronic migrain prevent
fda approv decis abp trastuzumab biosimilar breast cancer
phase data abp inflixibmab biosimilar rheumatoid arthriti
potenti approv pfe epogen biosimilar
aha updat treatment guidelin
european approv decis even romosozumab postmenopaus osteoporosi
potenti resubmiss bla even romosozumab postmenopaus osteoporosi
fda approv decis kyproli snda updat label includ os data
european approv decis kyproli variat updat label includ os data
potenti european approv decis abp biosimilar avastin oncolog indic
european approv decis blincyto variat updat label includ os data tower
european approv decis xgeva variat includ prevent sre multipl myeloma
launch amjevita biosimilar humira europ
cowen compani
cowen compani
growth growth aranesp y/i erythropoietin enbrel growth sale g-csf growth dmab growth kyproli growth product sale growth revenu growth good sold margin develop margin product incom growth growth ep includ stock share outstand ep exclud fasb abp stock compens expens merger-rel item ep cowen
cowen compani
 aranesp y/i erythropoietin enbrel growth sale g-csf growth dmab growth kyproli growth product sale growth revenu growth good sold margin develop loss affili margin product incom growth ep includ stock share outstand ep exclud fasb abp stock compens expens merger-rel item ep cowen
cowen compani
oper activitiesnet acquir in-process d- depreci base compens defer incom pp impairments- chang work capit less provid oper invest activ purchas /sale /proce market net use invest financ activitiesproce issuanc common common net provid financ cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
base busi compris mostli older biolog could experi biosimilar
competit impact difficult ass paid reason
sum acquir lead candid kyproli drug uncertain
sale potenti manag outlin strategi return cash sharehold
deviat plan could creat stock weak volatil much perceiv
valu within pipelin focus anti-cgrp anti-sclerostin
associ regulatori commerci risk
